NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN...
-
Upload
delphia-hodges -
Category
Documents
-
view
217 -
download
0
Transcript of NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN...
![Page 1: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/1.jpg)
NUCLEAR CARDIAC IMAGING
K.Michalová
Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol
![Page 2: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/2.jpg)
2. Ventricular Function
1. Myocardial Perfusion
3. Cardiac Metabolism and Myocardial Viability
4. Myocardial Innervation
Nuclear medicine methods in Cardiology are available for the evaluation of
5. Infarct Imaging
Kupka K .a kol: Nukleární medicína, 2007
![Page 3: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/3.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
This test is designed to evaluate regional myocardial perfusion under rest and stress condition in order to define regional myocardial perfusion reserve.
![Page 4: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/4.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
It involves the injecton of a radiolabelled substance which is extracted by the myocardium and accumulates in proportion to myocardial blood flow.Such radipharmaceuticals are injected under stress as well as resting conditions, and images are obtained to define the regional distribution of radioactivity within the myocardium.
![Page 5: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/5.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
The main indication is the detection and localization
of myocardial ischaemia or scar.
![Page 6: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/6.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
Myocardial ischaemia is defined as a perfusion defect present during stress but not resting conditions.Scar tissue is associated with a relative perfusion defect at rest as well as under stress.
![Page 7: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/7.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
RADIOPHARMACEUTICALS
201Thallium
99mTc-Labeled Myocardial Perfusion Agents
99mTc-SESTAMIBI (MIBI, 2-methoxy-isobutyl-isonitril, Cardiolite, CardioSPECT…)
99mTc-Tetrofosmin (Myoview) 99mTc-Teboroxim
![Page 8: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/8.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
201Thallium
- is an analog of potassium- it is actively transported into cardiac muscle via the sodium-potassium ATPase pump
![Page 9: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/9.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
201Thallium
- is a cyclotron-produced radiopharmaceutical
- emits x-rays of energy 69- to 83 keV
- physical half-life is 74 h
![Page 10: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/10.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
99mTc-SESTAMIBI x 201THALLIUM
ADVANTAGES :
- increased myocardial count density - lower radiation doses - no wash out of myocardium
![Page 11: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/11.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
99mTc-SESTAMIBI
= is a lipophilic cationic Tc-99m complex - it enteres pasivelly into the cells - and binds at the intracells membranes, especially of mitochondrials - it does not wash out of the myocardium in 3-4 hours
Tc-99m-Labeled Myocardial Perfusion Agents
![Page 12: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/12.jpg)
MYOCARDIAL PERFUSION SCINTIGRAPHY
99mTc-SESTAMIBI
99mTc - gamma rays of energy 140 keV - half life T1/2 = 6 hours
![Page 13: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/13.jpg)
![Page 14: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/14.jpg)
Exercise
Two-Day Patient Protocol
Delay Time (Intervals)
Injection - Imaging 15 min 60-90 min
Rest
Dose 700 MBq 700 MBq
Position Supine or prone Supine or prone
![Page 15: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/15.jpg)
Exercise Stress
* is performed by cardiologist * graded stress is usually performed with bicycle ergometr * it is necessary to reach the gender and age predicted 85% maximal heart rate * suboptimal stress level reduce sensitivity of this procedure for detection of CAD * the radiopharmaceutical is injected 1-2 minut before end of exercise
![Page 16: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/16.jpg)
![Page 17: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/17.jpg)
Pharmacologic Stress
Patients who are unable to exercisefor non cardiac reasons - e.g.arthritis, amputation, neurologic diseases or cardiac reasons - with LBBBmay be stress farmacologically
![Page 18: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/18.jpg)
Pharmacologic Stress
* vasodilators : adenosine dipyridamole* inotropic : dobutamine
![Page 19: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/19.jpg)
Pharmacologic Stress using dipyridamole
* mechanism of action different from exercise* directly tests flow reserve* dipyridamol causes vasodilatation* normal vessel vasodilate, increasing flow five times* stenotic vessels are already maximally vasodilatated, cannot increase flow* results in heterogenity on scan * does not depend on induction of ischemia* Heart rate increases 13 beats per minute (20%)* Blood pressure decreases 6 mm Hg (2 ti 8%)* Contraindication: Asthma bronchiale
![Page 20: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/20.jpg)
Pharmacologic Stress produced by dobutamine
* similar to exercise* indirectly tests flow reserve* increases myocardial oxygen consumption1) chronotropic effects2) ionotropic effects
![Page 21: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/21.jpg)
Acquisition SPECT study Dual head gamma camera moves around the patient viewing the object in 180 degrees in 64 steps for 25 seconds
45 deg.RAO
135 deg. LPO
![Page 22: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/22.jpg)
![Page 23: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/23.jpg)
GATED SPECT study
• ECG is acquired at the time of the SPECT acquisition • for simultaneous assessment of perfusion and function of the left ventricle in one examination evaluation of regional wall motion ejection fraction systolic thickening of the walls
![Page 24: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/24.jpg)
GATED SPECT study
We obtain myocardial perfusion images within one representative cardiac cycle : from end-diastole through end-systole to end-diastole of next cardiac cycle
Kamínek M. et al. : Atlas of Nuclear Cardiology, 2003
![Page 25: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/25.jpg)
Initial Displayof selected study-Reconstruction
With ellipse we selectregion of the heartin anterior viewin left lateral view.
The selected data setsare processed.
We must alignment axes of heartfor creation of the vertical long and short axis tomograms
Summed image-added multiple projec-tion images
![Page 26: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/26.jpg)
99m Tc-MIBI
slices in the short axis
slices in the long axis vertical
slices in the long axis horisontal
![Page 27: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/27.jpg)
![Page 28: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/28.jpg)
MYOCARDIAL ISCHEMIA
Can be identified by comparingthe results of exercise-injected studies and rest images .
As narrowing of coronary vessel approaches 70%lesion is hemodynamically significant during exercise.
![Page 29: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/29.jpg)
99m-Tc-MIBI
![Page 30: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/30.jpg)
Polar maps
Short axis slices are sequentially diplayed frombase to apex.
Conical myocardium is transformed into a disk.
![Page 31: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/31.jpg)
![Page 32: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/32.jpg)
![Page 33: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/33.jpg)
MYOCARDIAL PERFUSION IMAGING
INTERPRETATION CRITERIA
1. NORMAL FINDINGS
2. REVERSIBILE DEFECT - lesion is seen at stress and improves on the rest - is usually due to ischemia
3. NONREVERSIBILE DEFECT - lesion at rest is usually associated with myocardial scar or with severe ischemia.
![Page 34: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/34.jpg)
NORMAL FINDING
57 yo MALE
![Page 35: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/35.jpg)
REVERSIBILE DEFECT
![Page 36: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/36.jpg)
NONREVERSIBILE DEFECT
![Page 37: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/37.jpg)
MYOCARDIAL PERFUSION IMAGING
Clinical Indications
Diagnosis of coronary artery disease - presence - location (coronary territory) -extent (number of vascular territories involved)Determine prognosis
Society of Nuclear Medicine Procedure Guideline for Myocardial Perfusion Imaging
![Page 38: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/38.jpg)
MYOCARDIAL PERFUSION IMAGING
Clinical Indications
Determination of the significance of anatomic lesions detected by angiography
![Page 39: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/39.jpg)
MYOCARDIAL PERFUSION IMAGING
Clinical Indications
Monitoring treatment effect after coronary revascularization
![Page 40: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/40.jpg)
MYOCARDIAL PERFUSION IMAGING
Determine prognosis risk stratification
*Patients with normal perfusion imaging after adequate stress have a very low cardiac event rate independently of the presence or absence of angiographic CAD (yearly rate of myocardial infarction or death of less than 1%).
*A benign prognosis is asociated with a small fixed defectand a normal global left ventricle function.
![Page 41: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/41.jpg)
57 yo MALE
![Page 42: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/42.jpg)
MYOCARDIAL PERFUSION IMAGING
Determine prognosis risk stratification
* The risk of cardiac event can be suspected in all patients with the reversible perfusion defect.
* A higher risk can be expected in patients with a large perfusion defect, when more territories are affected, if the anterior wall is affected or if signs of postress dysfunction appear (transient ischemic dilation, deterioration of postress EF, increased uptake 201Tl in the lungs).
![Page 43: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/43.jpg)
![Page 44: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/44.jpg)
MYOCARDIAL VIABILITY
detection of myocardial viability has clinical importance for
- patients with chronic ischaemic left ventricular dysfunction and low left ventricle ejection fraction it is necessary to know, if defect of myocardial perfusion is
- ischemia vs. scar - predict improvement in function following revascularization
![Page 45: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/45.jpg)
REQUIREMENTS FOR CELLULAR VIABILITY
-adequate myocardial blood flow-sarcolemmal metabolic integrity-preserved metabolic activity
![Page 46: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/46.jpg)
MYOCARDIAL VIABILITY
The gold standard method
evaluation of myocardial glucose utilisation with fluorine-18 fluorodeoxyglucose (FDG)and positron emission tomography (PET)
![Page 47: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/47.jpg)
MYOCARDIAL VIABILITY
Principle Under fasting conditions the normal myocardium primarily utilises free fatty acids. In ischaemic myocardium glucose becomes an important energy substrate, FDG uptake will be enhanced.
![Page 48: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/48.jpg)
VIABLE MYOCARDIUMis characteristic in
NONREVERSIBILE PERFUSION DEFECT ( 99m-Tc MIBI) vs. PRESERVED MYOCARDIAL METABOLISM (18-FDG) = mismatch
![Page 49: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/49.jpg)
99mTc MIBI
18FDG
non viable
match
viable
mismatch
- we can expect improvement in function following revascularization
![Page 50: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/50.jpg)
99m-Tc-MIBI
![Page 51: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/51.jpg)
SCARis characteristic in
NONREVERSIBILE PERFUSION DEFECT ( 99m-Tc MIBI) vs. NO PRESERVED MYOCARDIAL METABOLISM (18-FDG )
= match
![Page 52: NUCLEAR CARDIAC IMAGING K.Michalová Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol.](https://reader036.fdocuments.us/reader036/viewer/2022062518/56649e385503460f94b288ee/html5/thumbnails/52.jpg)
99mTc MIBI
18FDG
nonviable
match
viable
mismatch
- we can´t expect improvement in function following revascularization